Key Highlights

  • Acumen Pharmaceuticals is trading down 85.77% at $0.33 after its Phase 2 Alzheimer's trial missed its primary endpoint.
  • SmartKem is trading down 25.96% at $0.304, below its 52-week low of $0.40.
  • FingerMotion is trading down 24.28% at $0.108, with cash of only $68,596 at fiscal year-end.
  • INLIF has lost about 92% from its $2.55 close on Oct 16 (calculation from the reported prices), after a registered direct offering.
  • The average decline across the five stocks is 35.42% (calculated).

Which Sub-$1 Penny Stocks Are Falling the Most Today?

Five stocks priced below $1 are posting the largest declines in this ranking on Oct 30, 2026, ordered by the size of the drop. Acumen Pharmaceuticals (NASDAQ:ABOS) is trading down 85.77% at $0.33, SmartKem (NASDAQ:SMTK) is down 25.96% at $0.304, FingerMotion (NASDAQ:FNGR) is down 24.28% at $0.108, INLIF (NASDAQ:INLF) is down 20.79% at $0.2099 and NetClass Technology (NASDAQ:NTCL) is down 20.29% at $0.4305.

Each percentage is measured against that stock's own prior close, so the bases differ, and several of these companies have been through reverse stock splits that distort older price comparisons. The ranking describes price moves only and carries no view on any company's outlook.

Acumen is the only name with a clear same-day announcement, a failed clinical trial. For SmartKem, FingerMotion, INLIF and NetClass, no company announcement dated today was identified, so the context below comes from recent filings rather than a proven cause. Readers should treat several of the supporting figures, such as older market values and 52-week ranges, as approximate because they come from earlier data snapshots.

1. Acumen Pharmaceuticals: why did the stock collapse 85.77% to $0.33?

Acumen reported that its Phase 2 ALTITUDE-AD study of sabirnetug in early Alzheimer's disease did not meet its primary endpoint at either dose tested, and key secondary endpoints also missed. The trial enrolled 542 participants, and amyloid plaque fell at both doses without a measurable gain in cognition or function.

The company said it will stop developing sabirnetug and evaluate strategic options, including its Enhanced Brain Delivery program. It held $110.2 million in cash and marketable securities at June 30, 2026, and said that funded operations into early 2027. Using about 72.3 million shares, the Market Value now works out to roughly $24 million, a rough estimate. Research and Development expense fell to $27.8 million in the second quarter, but the company has not said how much it plans to cut costs.

2. SmartKem: what is weighing on the stock after a 25.96% fall to $0.304?

SmartKem is trading down 25.96% at $0.304, from a prior close near $0.41, and no company announcement dated today was found. The price is below the 52-week low of $0.40 and well under the $2.35 last-sale price cited in a Sept 16 filing.

The company makes custom electronic materials, including its TRUFLEX line. Recent filings show a 1-for-50 reverse split in August, an Equity purchase agreement allowing sales of up to $500 million of shares and a pending all-stock Merger with Ferrox Critical Minerals valued at about $125 million. Auditors included going-concern paragraphs in the 2025 and 2024 financial statements.

3. FingerMotion: why is the stock down 24.28% to $0.108 despite lower costs?

FingerMotion is trading down 24.28% at $0.108, from a prior close near $0.143, with no same-day announcement identified. For the year ended Feb 28, 2026, Revenue fell 32% to $24.13 million and net loss widened 37% to $7.0 million, even though operating expenses fell 12% to $7.63 million.

The Singapore-based company provides mobile payment and recharge services, Data Analytics and digital applications, mainly in China. Cash was just $68,596 at year-end, and a $5 million convertible note issued on May 13, 2026 carries a $0.94 fixed conversion price, far above today's level. A data page placed the 52-week range at $0.13 to $1.74 as of Oct 19, so the stock now sits below that low.

4. INLIF: how much of the 20.79% drop to $0.2099 traces to the October offering?

INLIF is trading down 20.79% at $0.2099. No new company announcement was identified today, but the slide follows a registered direct offering revealed on Oct 19, when the stock fell about 84% from a $2.55 close to roughly $0.41. The offering priced shares at $1.60 with Series A, B and C warrants and raised about $3.75 million.

The Series A and B exercise prices carry a one-time downward reset, and the Series C formula can add shares if the price stays low. INLIF makes manipulator arms for injection molding machines through its China-based operating business. Reported first-half 2026 revenue rose 26.01% to $12.94 million with Net Income of $1.01 million, but the reported $45.47 million cash balance looks inconsistent with the small raise and remains unverified.

5. NetClass Technology: why did shares drop 20.29% below the 52-week low?

NetClass is trading down 20.29% at $0.4305, under the 52-week low of $0.6316 shown in market data as of Oct 27. No company-specific announcement was identified, and the latest corporate news found was the Oct 9 launch of the LinkeeBot AI pet through a joint venture in which NetClass holds 40%.

The Singapore and Hong Kong-based company sells business-to-business education software. Fiscal 2025 revenue was $9.81 million, down 2.94%, with a net loss of $10.82 million. Market data from Oct 27 showed a Capitalization near $1.79 million after a 1-for-50 share consolidation, and no cash figure was available in the sources reviewed.

Sub-$1 Decliners Compared: Average Decline, Spread and Price Gap

The five declines average 35.42% (calculated), though Acumen's 85.77% pulls that figure up sharply. Excluding Acumen, the other four average 22.83% (calculated), and they sit in a narrow band between 20.29% and 25.96%.

The spread between the largest and smallest decline is 65.48 percentage points (calculated). Acumen's drop is also about 3.30 times SmartKem's, the next largest (calculated). On price, NetClass at $0.4305 is roughly 3.99 times FingerMotion's $0.108 (calculated). Bases differ, since some stocks trade on post-reverse-split prices, and only Acumen's fall has a clear same-day announcement.

What to Watch Next: Acumen Data, the Ferrox Deadline and Warrant Resets

Acumen said further fluid biomarker and imaging data are due in the coming weeks, along with cash conservation details. SmartKem's merger agreement lets either side terminate if the Ferrox deal is not completed by Mar 31, 2027, and Shareholder votes plus an effective Form S-4 are still required.

FingerMotion's convertible note matures one year after its May 2026 closing, and any stockholder vote on additional conversion shares would matter. INLIF's warrants reset on the twentieth trading day after the Oct 20, 2026 closing, with no calendar date given in the sources. NetClass has no confirmed Earnings date, so no dated release was identified for it.